359 related articles for article (PubMed ID: 29409903)
21. Potential acetylcholinesterase inhibitors to treat Alzheimer's disease.
Saud A; Krishnaraju V; Taha A; Kalpana K; Malarkodi V; Durgaramani S; Vinoth Prabhu V; Saleh FA; Ezhilarasan S
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2522-2537. PubMed ID: 38567612
[TBL] [Abstract][Full Text] [Related]
22. Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
Tasso B; Catto M; Nicolotti O; Novelli F; Tonelli M; Giangreco I; Pisani L; Sparatore A; Boido V; Carotti A; Sparatore F
Eur J Med Chem; 2011 Jun; 46(6):2170-84. PubMed ID: 21459491
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease.
Korabecny J; Musilek K; Holas O; Binder J; Zemek F; Marek J; Pohanka M; Opletalova V; Dohnal V; Kuca K
Bioorg Med Chem Lett; 2010 Oct; 20(20):6093-5. PubMed ID: 20817518
[TBL] [Abstract][Full Text] [Related]
24. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
Eskander MF; Nagykery NG; Leung EY; Khelghati B; Geula C
Brain Res; 2005 Oct; 1060(1-2):144-52. PubMed ID: 16212945
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
[TBL] [Abstract][Full Text] [Related]
26. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
[TBL] [Abstract][Full Text] [Related]
27. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of imperatorin analogs and their evaluation as acetylcholinesterase and butyrylcholinesterase inhibitors.
Granica S; Kiss AK; Jarończyk M; Maurin JK; Mazurek AP; Czarnocki Z
Arch Pharm (Weinheim); 2013 Nov; 346(11):775-82. PubMed ID: 24123207
[TBL] [Abstract][Full Text] [Related]
29. N-alkylpiperidine carbamates as potential anti-Alzheimer's agents.
Košak U; Strašek N; Knez D; Jukič M; Žakelj S; Zahirović A; Pišlar A; Brazzolotto X; Nachon F; Kos J; Gobec S
Eur J Med Chem; 2020 Jul; 197():112282. PubMed ID: 32380361
[TBL] [Abstract][Full Text] [Related]
30. Butyrylcholinesterase in lipid metabolism: A new outlook.
Gok M; Cicek C; Bodur E
J Neurochem; 2024 Apr; 168(4):381-385. PubMed ID: 37129444
[TBL] [Abstract][Full Text] [Related]
31. One-pot synthesis of tetrazole-1,2,5,6-tetrahydronicotinonitriles and cholinesterase inhibition: Probing the plausible reaction mechanism via computational studies.
Hameed A; Zehra ST; Abbas S; Nisa RU; Mahmood T; Ayub K; Al-Rashida M; Bajorath J; Khan KM; Iqbal J
Bioorg Chem; 2016 Apr; 65():38-47. PubMed ID: 26851737
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of two different cholinesterases by tacrine.
Ahmed M; Rocha JB; Corrêa M; Mazzanti CM; Zanin RF; Morsch AL; Morsch VM; Schetinger MR
Chem Biol Interact; 2006 Aug; 162(2):165-71. PubMed ID: 16860785
[TBL] [Abstract][Full Text] [Related]
33. Attenuation of spatial memory in 5xFAD mice by targeting cholinesterases, oxidative stress and inflammatory signaling using 2-(hydroxyl-(2-nitrophenyl)methyl)cyclopentanone.
Ullah R; Ali G; Subhan F; Khan A; Ahsan Halim S; Naveed M; Kalsoom S; Al-Harrasi A
Int Immunopharmacol; 2021 Nov; 100():108083. PubMed ID: 34478946
[TBL] [Abstract][Full Text] [Related]
34. Identification of Compounds for Butyrylcholinesterase Inhibition.
Li S; Li AJ; Travers J; Xu T; Sakamuru S; Klumpp-Thomas C; Huang R; Xia M
SLAS Discov; 2021 Dec; 26(10):1355-1364. PubMed ID: 34269114
[TBL] [Abstract][Full Text] [Related]
35. Pharmacophore-based drug design of AChE and BChE dual inhibitors as potential anti-Alzheimer's disease agents.
Gao H; Jiang Y; Zhan J; Sun Y
Bioorg Chem; 2021 Sep; 114():105149. PubMed ID: 34252860
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, biological evaluation and docking studies of 2,3-dihydroquinazolin-4(1H)-one derivatives as inhibitors of cholinesterases.
Sarfraz M; Sultana N; Rashid U; Akram MS; Sadiq A; Tariq MI
Bioorg Chem; 2017 Feb; 70():237-244. PubMed ID: 28126287
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Acetylcholinesterase and Butyrylcholinesterase by a Plant Secondary Metabolite Boldine.
Kostelnik A; Pohanka M
Biomed Res Int; 2018; 2018():9634349. PubMed ID: 29850593
[TBL] [Abstract][Full Text] [Related]
38. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Ballard CG
Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
[TBL] [Abstract][Full Text] [Related]
39. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
Giacobini E
Drugs Aging; 2001; 18(12):891-8. PubMed ID: 11888344
[TBL] [Abstract][Full Text] [Related]
40. 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
Schott Y; Decker M; Rommelspacher H; Lehmann J
Bioorg Med Chem Lett; 2006 Nov; 16(22):5840-3. PubMed ID: 16945529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
